Cellectis

Cellectis is a biotechnology company based in Paris, France, founded in 1999 by André Choulika and David Sourdive. The company specializes in gene editing and is focused on developing allogeneic CAR T-cell therapies for cancer treatment. Cellectis utilizes its proprietary TALEN® technology and PulseAgile electroporation system to create innovative therapies. The company went public in 2007 and is listed on NASDAQ since 2014. Cellectis offers precision gene-editing tools and a range of allogeneic CAR T-cell therapies, including UCART19, UCART22, and UCART20a, which target various cancers. The company collaborates with pharmaceutical partners like Servier and healthcare institutions such as MD Anderson Cancer Center to advance its therapies. With manufacturing facilities in Paris, New York, and Raleigh, NC, Cellectis aims to provide cost-effective and universally accessible cancer treatments, emphasizing scalable production and off-the-shelf solutions.